Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis

Lv, Shuzhen; Wang, Yunchao; Sun, Tao; Wan, Donggui; Sheng, Lijun; Li, Wei; Zhu, Huayun; Li, Yanping; Lu, Janice

doi:10.1159/000488202

Cited by 21 publications

(24 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 Although a subset of gastric disease has HER2 amplification, monoclonal antibodies against HER2 have demonstrated very limited success in GC, unlike the response seen in HER2 positive breast cancer. 5 It is clear that more work is needed to elucidate the underlying molecular drivers and resistance mechanisms in GC.…”

Section: Introductionmentioning

confidence: 99%

Gastric Cancer Heterogeneity and Clinical Outcomes

Sexton

Hallak

Uddin

et al. 2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

Gastric adenocarcinoma is a highly aggressive disease with poor overall survival. The aggressive nature of this disease is in part due to the high intra and inter tumoral heterogeneity and also due to the late diagnosis at presentation. Once progression occurs, treatment is more difficult due to the adaptation of tumors, which acquires resistance to commonly used chemotherapeutics. In this report, using publicly available data sets and pathway analysis, we highlight the vast heterogeneity of gastric cancer by investigating genes found to be significantly perturbed. We found several upregulated genes in the diffuse gastric cancer subtypes share similarity to gastric cancer as a whole which can be explained by the increase in this subtype of gastric cancer throughout the world. We report significant downregulation of genes that are underrepresented within the literature, such as ADH7, GCNT2, and LIF1, while other genes have not been explored within gastric cancer to the best of our knowledge such as METTL7A, MAL, CWD43, and SLC2A12. We identified gender to be another heterogeneous component of this disease and suggested targeted treatment strategies specific to this heterogeneity. In this study, we provide an in-depth exploration of the molecular landscape of gastric cancer in order to shed light onto novel areas of gastric cancer research and explore potential new therapeutic targets.

show abstract

Section: Introductionmentioning

confidence: 99%

Gastric Cancer Heterogeneity and Clinical Outcomes

Sexton

Hallak

Uddin

et al. 2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Some targeted therapeutics are already being used as the first line treatment for patients in the clinic, such as the monoclonal antibodies Herceptin and the newer pertuzumab that target the receptor HER2, which is overexpressed in cancers such as metastatic breast cancer [ 3 , 4 , 5 ]. Herceptin treatment in patients with HER2 overexpressing tumours results in significantly better survival rates [ 6 ]. Despite these advances in targeted therapies, continued progress into the understanding of cancer-specific markers, such as upregulated HER2, and the development of targeted treatments are required to improve patient survival further.…”

Section: Introductionmentioning

confidence: 99%

Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies

Cunliffe

Bates

Parker

2020

Cancers

View full text Add to dashboard Cite

More people are surviving longer with cancer. Whilst this can be partially attributed to advances in early detection of cancers, there is little doubt that the improvement in survival statistics is also due to the expansion in the spectrum of treatments available for efficacious treatment. Transformative amongst those are immunotherapies, which have proven effective agents for treating immunogenic forms of cancer, although immunologically “cold” tumour types remain refractive. Oncolytic viruses, such as those based on adenovirus, have great potential as anti-cancer agents and have seen a resurgence of interest in recent years. Amongst their many advantages is their ability to induce immunogenic cell death (ICD) of infected tumour cells, thus providing the alluring potential to synergise with immunotherapies by turning immunologically “cold” tumours “hot”. Additionally, enhanced immune mediated cell killing can be promoted through the local overexpression of immunological transgenes, encoded from within the engineered viral genome. To achieve this full potential requires the development of refined, tumour selective “precision virotherapies” that are extensively engineered to prevent off-target up take via native routes of infection and targeted to infect and replicate uniquely within malignantly transformed cells. Here, we review the latest advances towards this holy grail within the adenoviral field.

show abstract

“…Some targeted therapeutics are already being used as the first line treatment for patients in the clinic, such as the monoclonal antibodies, Herceptin and the newer Pertuzumab which target the receptor HER2, which is overexpressed in cancers such as metastatic breast cancer (Arteaga, 2003;Eiger et al, 2019;Vogel et al, 2002). Herceptin treatment in patients with HER2 overexpressing tumours results in significantly better survival rates (Lv et al, 2018). Despite these advances in targeted therapies, continued progress into the understanding of cancerspecific markers, like upregulated HER2, and the development of targeted treatments are required to improve patient survival further.…”

Section: Introductionmentioning

confidence: 99%

Hitting the Target but Missing the Point: Recent Progress Towards Adenovirus-Based Precision Virotherapies

Cunliffe¹,

Bates²,

Parker³

2020

Preprint

View full text Add to dashboard Cite

More people are surviving longer with cancer. Whilst this can be partially attributed to advances in early detection of cancers, there is little doubt that the improvement in survival statistics is also due to the expansion in the spectrum of treatments available for efficacious treatment. Transformative amongst those are immunotherapies, which have proven effective agents for treating immunogenic forms of cancer, though immunologically “cold” tumour types remain refractive. Oncolytic viruses, such as those based on adenovirus have great potential as anti-cancer agents and have seen a resurgence of interest in recent years. Amongst their many advantages is their ability to induce immunogenic cell death (ICD) of infected tumour cells, thus providing the alluring potential to synergize with immunotherapies by turning immunologically “cold” tumours “hot”. Additionally, enhanced immune mediated cell killing can be promoted through the local overexpression of immunological transgenes, encoded from within the engineered viral genome. To achieve this full potential requires the development of refined, tumour selective “precision virotherapies” that are extensively engineered to prevent off-target up take via native routes of infection, and targeted to infect and replicate uniquely within malignantly transformed cells. Here, we review the latest advances towards this holy grail within the adenoviral field.

show abstract

Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis

Cited by 21 publications

References 18 publications

Gastric Cancer Heterogeneity and Clinical Outcomes

Gastric Cancer Heterogeneity and Clinical Outcomes

Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies

Hitting the Target but Missing the Point: Recent Progress Towards Adenovirus-Based Precision Virotherapies

Contact Info

Product

Resources

About